REMDESIVIR IN COVID-19 AND EXPERIENCE AT THE NATIONAL RESEARCH CARDIAC SURGERY CENTER: «A CASE-CONTROL» RETROSPECTIVE STUDY
Introduction. The fight against COVID-19 has become a major problem for the whole world and it is necessary to accelerate the development of the strategy as much as possible. Currently, studies are ongoing, but cases of special clinical study of the drug remdesivir have been identified. It was shown that this antiviral drug has a good potential to combat COVID-19 in the short term [6], initiated by several studies by Beigel et al. (ACCT 1) [4], Goldman et al. [13] and Spinner et al. [15], to assess the safety and efficacy of remdesivir in patients with COVID-19 [16].
Aim: evaluation of the effectiveness of remdesivir in hospitalized patients with COVID-19 with a moderate course of the disease.
Materials and мethods: This study is retrospective. The methodology includes a retrospective analysis of the medical history of 295 moderately severe COVID-19 patients with prospective laboratory-confirmed PCR testing for SARS-CoV-2, presence of complicated pneumonia, increased chest imaging. The main group - 164 patients with included remdesivir in the treatment protocol.
The control group consisted of 131 patients who received therapy in accordance with the standard protocol for the treatment of COVID-19. Statistical analysis was performed using STATA/MP software. Normally distributed data and categorical variables are presented as mean standard deviation (mean (SD) and numbers with percentages, respectively. Between-group differences in categorical variables were assessed using a chi-square test. All tests were two-tailed, and a p value < 0.05 was considered statistically significant.
Results. The most end point in our study was the time to achieve/improve clinical status. Remdesivir showed a reduction in mean length of stay in hospital. Our study shows that remdesivir is superior to standard treatment. Also, from the results of our study, a great importance was found in the formation of pulmonary fibrosis in patients treated with remdesivir and in the control group of results with the most frequent formation of fibrosis in the first group of CT scans that found the results of the chest organs after 120–180 days from diseases.
Conclusions. Efficacy of remdesivir in hospitalized adult COVID-19 patients with moderate disease. Outcomes were assessed on three important outcome measures: duration of hospitalization, disease and laboratory tests, and need for mechanical ventilation (ALV). Based on these three criteria, this drug has shown good results in getting COVID-19 by all standards.
Number of Views: 149
Category of articles:
COVID-19 - Topical Subject
Bibliography link
Bekbossynova M.S., Tauyekelova A.Т., Sailybayeva А.I., Raimkulova A.T. Dalbekova М.К. Remdesivir in COVID-19 and experience at the National Research Cardiac Surgery Center: «A Case-control» retrospective study // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 2, pp. 7-15. doi 10.34689/SH.2023.25.2.001Related publications:
EPIDEMIOLOGICAL ASPECTS OF IN-STENT THROMBOSIS AND RESTENOSIS OF CORONARY ARTERIES IN PATIENTS WITH PREVIOUS REVASCULARIZATION AFTER CORONAVIRUS INFECTION
IMMUNOLOGICAL CHANGES IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2
EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
APPLICATION OF ARTIFICIAL INTELLIGENCE IN COMBATING THE COVID-19 PANDEMIC: CURRENT TRENDS AND PROSPECTS. REVIEW
CONSEQUENCES OF THE CORONAVIRUS INFECTION: THE POST-COVID SYNDROME AND MENTAL MANIFESTATIONS. LITERATURE REVIEW